Published in Expert Opin Investig Drugs on July 01, 2005
Dose Finding Study of CHF 4226 for Treating Patients With COPD | NCT00605891
Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis (2011) 1.35
β(2) -adrenoceptor agonists: current and future direction. Br J Pharmacol (2011) 1.30
Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol (2008) 1.28
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res (2010) 1.21
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res (2010) 1.12
Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res (2011) 1.01
Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm Med (2011) 0.98
The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br J Pharmacol (2009) 0.91
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis (2010) 0.90
Comparative efficacy of indacaterol in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2012) 0.89
Indacaterol: a comprehensive review. Int J Chron Obstruct Pulmon Dis (2013) 0.86
Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.79
A new target region for changing the substrate specificity of amine transaminases. Sci Rep (2015) 0.77
Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. J Drug Assess (2013) 0.77
Biological targets for therapeutic interventions in COPD: clinical potential. Int J Chron Obstruct Pulmon Dis (2006) 0.75
Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol. Ther Clin Risk Manag (2015) 0.75
Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet (2014) 0.75
Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles (2013) 4.05
Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol (2012) 3.18
Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J Transl Med (2011) 3.03
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med (2010) 2.56
Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J Immunol (2003) 2.50
Large scale questionnaire survey on respiratory health in Sweden: effects of late- and non-response. Respir Med (2009) 2.22
Isolation and characterization of RNA-containing exosomes. J Vis Exp (2012) 2.16
Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. J Extracell Vesicles (2013) 2.08
Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann Allergy Asthma Immunol (2012) 1.97
Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. PLoS One (2010) 1.94
Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol (2002) 1.63
Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med (2012) 1.57
Characterization of mRNA and microRNA in human mast cell-derived exosomes and their transfer to other mast cells and blood CD34 progenitor cells. J Extracell Vesicles (2012) 1.52
Importance of RNA isolation methods for analysis of exosomal RNA: evaluation of different methods. Mol Immunol (2012) 1.52
Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway inflammation. Am J Respir Cell Mol Biol (2005) 1.48
Pharmacological modulation of interleukin-17-induced GCP-2-, GRO-alpha- and interleukin-8 release in human bronchial epithelial cells. Eur J Pharmacol (2003) 1.45
The influence of personality traits and beliefs about medicines on adherence to asthma treatment. Prim Care Respir J (2011) 1.38
EVpedia: an integrated database of high-throughput data for systemic analyses of extracellular vesicles. J Extracell Vesicles (2013) 1.34
The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther (2004) 1.31
β(2) -adrenoceptor agonists: current and future direction. Br J Pharmacol (2011) 1.30
Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano (2013) 1.23
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J (2013) 1.20
Patterns of airway inflammation and MMP-12 expression in smokers and ex-smokers with COPD. Respir Res (2007) 1.16
Past, present and future--beta2-adrenoceptor agonists in asthma management. Respir Med (2005) 1.13
Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax (2013) 1.08
Increased prevalence of symptoms of rhinitis but not of asthma between 1990 and 2008 in Swedish adults: comparisons of the ECRHS and GA²LEN surveys. PLoS One (2011) 1.05
The influence of personality traits on reported adherence to medication in individuals with chronic disease: an epidemiological study in West Sweden. PLoS One (2011) 1.04
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy (2012) 1.04
Eosinophil progenitors in allergy and asthma - do they matter? Pharmacol Ther (2008) 1.04
Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res (2011) 1.02
Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med (2004) 1.02
Triple combinations in chronic obstructive pulmonary disease - is three better than two? Expert Opin Pharmacother (2014) 1.02
Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA2LEN and InterAirways document. Allergy (2007) 1.01
Immunization with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses. J Immunol (2013) 1.00
Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clin Transl Allergy (2012) 0.97
Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respir Res (2011) 0.95
Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. BMC Pulm Med (2014) 0.95
RNA-containing exosomes in human nasal secretions. Am J Rhinol Allergy (2010) 0.94
Inflammation--a new therapeutic target in pneumonia. Respiration (2005) 0.94
Adult-onset asthma in west Sweden--incidence, sex differences and impact of occupational exposures. Respir Med (2011) 0.93
Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells--Evidence of unique microRNA cargos. RNA Biol (2015) 0.93
Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med (2012) 0.92
Eotaxin-2 regulates newly produced and CD34 airway eosinophils after allergen exposure. J Allergy Clin Immunol (2004) 0.91
Asthma in late adolescence--farm childhood is protective and the prevalence increase has levelled off. Pediatr Allergy Immunol (2010) 0.90
High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. Am J Respir Cell Mol Biol (2012) 0.90
Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother (2013) 0.90
Prevalence of chronic nasal symptoms in West Sweden: risk factors and relation to self-reported allergic rhinitis and lower respiratory symptoms. Int Arch Allergy Immunol (2010) 0.88
Mast cell exosomes promote lung adenocarcinoma cell proliferation - role of KIT-stem cell factor signaling. Cell Commun Signal (2014) 0.88
Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. COPD (2014) 0.87
An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs (2012) 0.87
Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther (2013) 0.87
Levalbuterol has not been established to have therapeutic advantage over racemic albuterol. J Allergy Clin Immunol (2002) 0.87
Rhinitis phenotypes correlate with different symptom presentation and risk factor patterns of asthma. Respir Med (2011) 0.87
To add, or not to add an inhaled corticosteroid in moderate COPD: that is the question. Chest (2008) 0.87
Questionnaire layout and wording influence prevalence and risk estimates of respiratory symptoms in a population cohort. Clin Respir J (2012) 0.86
Safety of long-acting beta2-agonists in the treatment of asthma. Ther Adv Respir Dis (2007) 0.86
Regulation of bone marrow and airway CD34+ eosinophils by interleukin-5. Am J Respir Cell Mol Biol (2003) 0.85
New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther (2013) 0.85
Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9. Respir Res (2005) 0.85
Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther (2012) 0.85
Proteomics in asthma and COPD phenotypes and endotypes for biomarker discovery and improved understanding of disease entities. J Proteomics (2011) 0.84
Respiratory symptoms and respiratory-related absence from work among health care workers in Sweden. J Asthma (2013) 0.84
Allergen exposure-induced differences in CD34+ cell phenotype: relationship to eosinophilopoietic responses in different compartments. Blood (2003) 0.84
The function of medication beliefs as mediators between personality traits and adherence behavior in people with asthma. Patient Prefer Adherence (2013) 0.84
Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma. Ther Adv Respir Dis (2013) 0.83
IL-17 in chronic obstructive pulmonary disease. Expert Rev Respir Med (2012) 0.83
Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD. J Clin Pharmacol (2008) 0.83
Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet (2002) 0.83
Allergen-induced traffic of bone marrow eosinophils, neutrophils and lymphocytes to airways. Eur J Immunol (2004) 0.83
Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. Respir Res (2014) 0.83
Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol (2015) 0.83
Recent educational interventions for improvement of asthma medication adherence. Asia Pac Allergy (2012) 0.83
Local proliferation and mobilization of CCR3(+) CD34(+) eosinophil-lineage-committed cells in the lung. Immunology (2010) 0.83
MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma. BMC Cancer (2014) 0.83
Network analysis of quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment. Respir Res (2011) 0.82
Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother (2013) 0.82
The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle. Pulm Pharmacol Ther (2013) 0.82
Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression. PLoS One (2011) 0.82
Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. Chest (2004) 0.82
The use of bronchodilators in the treatment of airway obstruction in elderly patients. Pulm Pharmacol Ther (2005) 0.81
Exosome as a novel shuttle for innovation. Preface. Adv Drug Deliv Rev (2013) 0.81
Pulmonary inflammation induced by bacteria-free outer membrane vesicles from Pseudomonas aeruginosa. Am J Respir Cell Mol Biol (2013) 0.81
Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium. Pharmacology (2014) 0.81
The future of combining inhaled drugs for COPD. Curr Opin Pharmacol (2012) 0.81
Beta-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution. Am J Respir Crit Care Med (2008) 0.81
Higher risk of wheeze in female than male smokers. Results from the Swedish GA 2 LEN study. PLoS One (2013) 0.81
Oxidation pathway and exacerbations in COPD: the role of NAC. Expert Rev Respir Med (2015) 0.81
Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD. Pulm Pharmacol Ther (2010) 0.80
Motivational foci and asthma medication tactics directed towards a functional day. BMC Public Health (2011) 0.80
Immunophenotyping of circulating T helper cells argues for multiple functions and plasticity of T cells in vivo in humans--possible role in asthma. PLoS One (2012) 0.80
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. Respir Med (2013) 0.80
B cells: from early development to regulating allergic diseases. Arch Immunol Ther Exp (Warsz) (2010) 0.80
Macrolide and occult infection in asthma. Curr Opin Pulm Med (2004) 0.80
Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD. Respiration (2004) 0.79
Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD. Respir Med (2012) 0.79
Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. Chest (2005) 0.79
Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. Am J Respir Cell Mol Biol (2011) 0.79